StockUS listing USEWNYSEHealthcareQuality Compounder

Edwards Lifesciences Corp(EW) Stock Analysis | Healthcare

USD --+0.00%
Reward50Moderate
Risk26Low
75%Data
Strong 15% profit margin · Revenue growing 11% YoY
USD —+0.00 (+0.00%) Previous close · NYSE
Market cap 58.56Bn
Reward Ratingⓘ50 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ26 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on EW to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Edwards Lifesciences Corp?

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.

AI Brief Pro

The brief on Edwards Lifesciences Corp

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Edwards Lifesciences Corp?

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 58.56B, and a P/E ratio of 59.2x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (50)

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryMedical Devices
P/E Ratio59.2151
Beta0.832
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
11110,085 shares
$10.9M
0
3-6months
938,787.39 shares
$3.3M
0
6-9months
0
0
9-12months
0
0